Beijing pharmaceutical companies shocked the anti-tumor drug Pfizer, which soared 400%, sold $5 billion globally

Medical Network, July 14 News On July 9th, Beijing Tide Pharmaceutical submitted an application for the generic listing of Pipercillil Capsules for 4 types of generic listings and was contracted by CDE
.
Pipercillil is Pfizer's blockbuster anti-tumor drug, with global sales of up to 5 billion US dollars in 2020, of which capsules were approved to enter the domestic market in July 2018
.
Figure 1: Source of the latest product information: Pfizer’s pipercillil capsules from CDE’s official website were approved to enter the domestic market in July 2018 for use in combination with aromatase inhibitors as locally advanced or metastatic HR+, HER2-menopause After initial endocrine therapy in female breast cancer patients
.
At present, it has not yet entered the medical insurance, so the sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) have not yet increased.
In 2020, there will only be 60 million yuan
.
Figure 2: The sales of piperazil capsules in physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mynet.
com China’s urban physical pharmacies terminal layout.
According to data from Mynet.
com, pibacillil capsules are exploding in physical pharmacies in Chinese cities.
Growth, sales in 2020 have been ahead of China's public medical institutions, the growth rate is as high as 438%
.
Figure 3: Approval status of piperazil capsules.
Source: One-click search by Meinenet.
Qilu's 4 types of imitations were approved in 2020 and deemed to have been reviewed.
Currently, Nanjing Simcere TECO Pharmaceuticals, Hausen Pharmaceuticals, Osaikang, and Ke The listing applications of 5 companies including Lun are under review and approval.
After Beijing Tide Pharmaceutical enters the market, the market competition for this product will become more intense in the future
.
Source: Mi Nei.
com database The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.